President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.

Karen Fernandez, MD, discusses the different types of treatment currently being tested for use in dry eye disease, which affects millions in the US.

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax(R) Ophthalmic Suspension, 0.5%, of Bausch & ...